Browse by Current Cardiff authors
Number of items: 12.
Hole, Paul Spencer, Zabkiewicz, Joanna, Munje, Chinmay, Newton, Zarabeth, Pearn, Lorna, White, Paul Charles, Marquez, Nuria, Hills, Robert Kerrin, Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence
2013.
Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling.
Blood
122
(19)
, pp. 3322-3330.
10.1182/blood-2013-04-491944
|
|
Knapper, Steven, White, Paul Charles, Levis, Mark J., Hills, Robert Kerrin, Russell, Nigel H. and Burnett, Alan Kenneth
2011.
The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials.
Blood -New York-
118
(21)
, p. 194.
|
|
Pallis, M, Hills, Robert Kerrin, White, Paul Charles, Grundy, M, Russell, N and Burnett, Alan Kenneth
2011.
Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial.
Blood Cancer Journal
1
, e23.
|
|
Sato, Takashi, Yang, Xiaochuan, Knapper, Steven, White, Paul Charles, Smith, B. Douglas, Galkin, Steven, Small, Donald, Burnett, Alan Kenneth and Levis, Mark
2011.
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Blood
117
(12)
, pp. 3286-3293.
10.1182/blood-2010-01-266742
|
|
Pallis, M., White, Paul Charles, Hills, Robert Kerrin, Grundy, M., Russell, N. H. and Burnett, Alan Kenneth
2010.
Analysis of the interaction of induction regimens with P-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 Trial [Abstract].
Blood
116
(21)
, p. 1123.
|
|
Freeman, S., Hills, Robert Kerrin, Virgo, P., Couzens, Stephen, Lowdell, M. W., McNamara, C. J., White, Paul Charles and Burnett, Alan Kenneth
2010.
Detection of immunophenotypic residual disease after induction therapy is an independent prognostic factor for duration of remission in older AML patients treated intensively [Abstract].
Blood
116
(21)
, pp. 1118-1119.
|
|
Tonks, Alex, Hills, Robert Kerrin, White, Paul Charles, Rosie, B., Mills, Kenneth Ian, Burnett, Alan Kenneth and Darley, Richard Lawrence
2007.
CD200 as a prognostic factor in acute myeloid leukaemia.
Leukemia
21
(3)
, pp. 566-568.
10.1038/sj.leu.2404559
|
|
Tonks, Alex, Hills, Robert Kerrin, White, Paul Charles, Rosie, B., Mills, Kenneth Ian, Burnett, Alan Kenneth and Darley, Richard Lawrence
2007.
CD200 as a prognostic factor in acute myeloid leukaemia [Letter].
Leukemia
21
(3)
, pp. 566-568.
10.1038/sj.leu.2404559
|
|
Seedhouse, C. H., Grundy, M., White, Paul Charles, Li, Y., Fisher, Janet, Yakunina, Darya, Moorman, A. V., Hoy, Terence, Russell, N., Burnett, Alan Kenneth and Pallis, M.
2007.
Sequential Influences of Leukemia-Specific and Genetic Factors on P-glycoprotein expression in blasts from 817 patients entered into the national cancer research network acute myeloid leukemia 14 and 15 trials.
Clinical Cancer Research
13
(23)
, pp. 7059-7066.
10.1158/1078-0432.CCR-07-1484
|
|
Shore, Angharad M., White, Paul Charles, Hui, Rosaline C.-Y., Essafi, Abdelkader, Lam, Eric W.-F., Rowe, Martin and Brennan, Paul
2006.
Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A.
Journal of Virology
80
(22)
, pp. 11191-11199.
10.1128/JVI.00983-06
|
|
White, Paul Charles, Shore, A. M., Clement, Mathew, McLaren, James Edward, Soeiro, I., Lam, E. W.-F. and Brennan, Paul
2006.
Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes.
Oncogene
25
(15)
, pp. 2170-2180.
10.1038/sj.onc.1209255
|
|
This list was generated on Wed Jan 5 04:58:18 2022 GMT.